Nomogram to Predict Breast Cancer Related Lymphedema
Breast Cancer, Axillary Lymph Node Dissection, Breast Cancer Related Lymphedema
About this trial
This is an interventional prevention trial for Breast Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18 years or older with T1-3 invasive breast cancer;
- Clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast;
- Patients who underwent mastectomy with a positive sentinel lymph node (SLN);
- Patients who underwent breast-conserving surgery containing more than two positive SLNs.
Exclusion Criteria:
- Neoadjuvant chemotherapy;
- Previous history of breast cancer.
Sites / Locations
- Zhongnan Hospital of Wuhan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Axillary surgery based on lymphedema prediction nomogram
Standard axillary lymph node dissection
Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
Standard axillary lymph node dissection was performed with complete resection of Berg's levels I and II.